Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/ Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch.
Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting
News provided by
Share this article
Share this article
OXFORD, England, April 27, 2021 /PRNewswire/ Enesi Pharma ( Enesi ), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (WVC 2021, 4-6 May 2021), which this year is free to attend.
The presentation, entitled
Logistics, last-mile, and innovations to ensure successful deployment of next-generation COVID-19 vaccines, will also look at the development and application of Enesi s needle-free, unit solid-dose, thermally stable ImplaVax® platform and how it is enabling a number of vaccines of potential global significance. The presentation will take place at 14:30 EST on Thursday 6 May.
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company s ongoing vaccine developments for COVID-19.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA), will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed INOVIO: The decision results from the changing environment of
Argonne s Advanced Photon Source guided the development of new COVID-19 vaccine now in trials
Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world. The development of this new vaccine was guided by structural information on the virus obtained at the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science User Facility at DOE s Argonne National Laboratory, and other light sources.
Trials are taking place at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command, following up on early tests that showed promising results.